Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis

I Roos; E Leray; R Casey; D Horakova; E Havrdova; G Izquierdo; SE Madueño; F Patti; G Edan; M Debouverie; J Pelletier; S Ozakbas; MP Amato; P Clavelou; P Grammond; C Boz; K Buzzard; O Skibina; J Ciron; O Gerlach; F Grand'maison; J Lechner-Scott; C Malpas; H Butzkueven; S Vukusic; T Kalincik

Journal article

Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis

I Roos, E Leray, R Casey, D Horakova, E Havrdova, G Izquierdo, SE Madueño, F Patti, G Edan, M Debouverie, J Pelletier, S Ozakbas, MP Amato, P Clavelou, P Grammond, C Boz, K Buzzard, O Skibina, J Ciron, O Gerlach Show all

Neurology | Published : 2021

DOI: 10.1212/WNL.0000000000012354

Abstract

Objective: To compare the clinical effectiveness of high- and low-efficacy treatments in patients with recently active and inactive secondary progressive multiple sclerosis (SPMS) after accounting for therapeutic lag. Methods: Patients treated with high-efficacy (natalizumab, alemtuzumab, mitoxantrone, ocrelizumab, rituximab, cladribine, fingolimod) or low-efficacy (interferon beta, glatiramer acetate, teriflunomide) therapies after SPMS onset were selected from MSBase and Observatoire Français de la Sclérose en Plaques (OFSEP), 2 large observational cohorts. Therapeutic lag was estimated for each patient from their demographic and clinical characteristics. Propensity score was used to match..

View full abstract

University of Melbourne Researchers

Izanne Roos Author

Charles Malpas Author

Tomas Kalincik Author

Related Projects (3)

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

BIOMARKERS TO PREVENT DISABILITY IN MULTIPLE SCLEROSIS

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This study was supported by the EDMUS Foundation and National Health and Medical Research Council (1140766, 1129189, 1157717). I.R. is supported by a MSIF-ARSEP McDonald fellowship grant and a Melbourne Research Scholarship. The MSBase Foundation is a not-for-profit organization that receives support from Biogen, Novartis, Merck, Roche, Teva, and Sanofi Genzyme. OFSEP is supported by a grant provided by the French State and handled by the Agence Nationale de la Recherche, within the framework of the Investments for the Future program, under the reference ANR-10-COHO-002, by the Eugene Devic EDMUS Foundation against multiple sclerosis, and by the ARSEP Foundation.